Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced significant hair regrowth using a treatment regimen including finasteride, oral and topical minoxidil, RU58841, red light therapy, microneedling, and various supplements. They switched from dutasteride to finasteride due to side effects and reported improved results and well-being.

GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

Eucapil is discussed as a potential hair loss treatment with some believing it to be effective, though its efficacy compared to finasteride is debated. It is considered an anti-androgen treatment, often used alongside other treatments like minoxidil and finasteride, but lacks independent studies to fully support its effectiveness.

The user has been on a hair loss treatment for 14 months using dutasteride and oral minoxidil without seeing regrowth and is considering adding more drugs due to the psychological impact of hair loss. However, replies suggest the user may not actually be experiencing noticeable hair loss.

The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.

A hair loss regimen involving Dutasteride, Oral Minoxidil, Mesotherapy, Topical Minoxidil/Finasteride, RU58841, Alfatridiol, Microneedling, LLLT, Keto shampoo, Vitamin K/D/Fish oil/Borage Oil/MSM, Oral Castor oil and Niacin. It also mentions products that have been dropped from the regimen due to not being worth the hassle or messing with libido.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User asks for opinions on topical adenosine as a treatment.

The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

KX-826 Max combines KX-826, Kopyrrol, and Kopexil as a potential alternative to minoxidil and finasteride for hair loss, but users express skepticism about its effectiveness and high cost. Some users believe traditional treatments like minoxidil, finasteride, and others are more reliable.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.

The user has been using Finasteride for seven months to address hair loss but hasn't seen noticeable regrowth and is experiencing brittle, thinning hair with scalp issues. They are also using Salisia and Re’equil Salicylic Acid shampoo for potential psoriasis and are seeking advice from others with similar experiences.

A user shared their 7-month hairline recovery using 1 mg finasteride and 5 mg minoxidil daily. They experienced significant hair growth, including unwanted facial hair, and discussed potential side effects and dosage adjustments with others.

The conversation is about two new videos on exosomes, focusing on how they work and a Q&A session about their use. Specific treatments for hair loss are not discussed.

KX-826 stopped hair loss for the user after stopping finasteride due to mild side effects. The user experienced mild headaches initially with KX-826, which resolved after a few days.

The conversation is about using RU58841 for hair loss treatment, specifically mixing it with minoxidil without propylene glycol due to an allergy. The user is considering starting with a lower concentration of RU58841 and making smaller batches to maintain efficacy.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

The conversation discusses using a combination of redensyl, capixyl, and procapil (RCP) for hair loss, with some users also mentioning minoxidil and finasteride. Users shared mixed experiences, with some suggesting "RevivHair Max Hair Stimulating Serum" for better results, while others reported no noticeable effects from using products like The Ordinary Multi-Peptide Serum.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.